The manufacturer, GlaxoSmithKline (GSK), knew from its own data that the drug failed to outperform placebo and carried a serious risk of suicidal behaviour.

Instead of telling the truth, GSK hired a public-relations firm to ghostwrite the paper, enlisted academic co-authors who never saw the raw data, and used the publication to promote Paxil to doctors treating children.

It became known as Study 329 — one of the most infamous cases of scientific fraud in modern psychiatry.

For years, the fraud stood unchallenged. Regulators issued warnings but never forced a correction. The journal refused to retract. The paper remained in circulation — cited hundreds of times, shaping prescribing habits, and legitimising a lie that cost young lives.

https://brownstone.org/articles/study-329-the-big-fraud-is-finally-under-review/